The outcome of 45 AML1-ETO-positive acute myeloid leukemia (AML) patients was analyzed with special emphasis on the quality of molecular response to therapy. Patients received double induction therapy, either 6-thioguanine, cytarabine, and daunorubicin (TAD9)/high-dose cytosine arabinoside plus mitoxantrone (HAM) or HAM/HAM, followed by consolidation therapy (TAD9) according to the AML-Cooperative group 92 trial (AMLCG92) and AML-Cooperative group 99 trial (AMLCG99). All cases underwent cytomorphological, cytogenetical and molecular genetic analyses. AML1-ETO transcript levels were quantitatively assessed at diagnosis and during follow-up by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). The median reduction of initial AML1-ETO expression level was 4 log (range 0-5) after both induction and consolidation therapies. The quality of molecular response after induction as well as consolidation therapies had significant impact on the cumulative incidence of relapse (P ¼ 0.021 and P ¼ 0.001, respectively), event free survival (EFS: P ¼ 0.001 and P ¼ 0.001, respectively) and overall survival (OS: P ¼ 0.013 and P ¼ 0.014, respectively). HAM/HAM improved the molecular response to induction therapy (P ¼ 0.042) but after consolidation, no differences in molecular response were detectable between TAD9/HAM and HAM/HAM. Patient-or disease-related factors had no impact on the molecular response to induction or consolidation therapy. The current study demonstrates that quantification of AML1-ETO transcript levels is a powerful tool for prediction of prognosis that is independent of pretreatment risk factors, and may be helpful for directing therapeutic decisions in the future.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease, which is characterized by differences in cytomorphologic, cytogenetic and molecular features of leukemic subtypes. In particular, karyotype and molecular markers determine the response to therapy and not least the curative potential.
1-3 Thus it was possible to separate prognostic subgroups with a favorable outcome such as AML1-ETO and CBFB-MYH11-positive AML and promyelocytic leukemia-retinoic acid receptor a(PML-RARA)-positive APL, those with an intermediate prognosis such as a normal karyotype and those with poor prognostic chromosomal aberrations and complex aberrant karyotype in particular. The subtype with t(8;21)(q22;q22)/ AML1-ETO accounts for approximately 7-10% of AML cases. In t(8;21)-positive AML, the AML1 gene located in 21q22 is fused to the ETO gene located in 8q22, resulting in the fusion gene AML1-ETO. Polymerase chain reaction (PCR) techniques enable sensitive and specific detection of AML1-ETO fusion transcripts. The most sensitive method is nested reverse transcriptase-PCR (RT-PCR) that allows detection of one leukemic cell in 10 6 normal cells. It was previously shown that AML1-ETO fusion transcripts remain detectable throughout the course of therapy and even in patients in long-term remission. [4] [5] [6] [7] [8] [9] [10] [11] Although this persistence of AML1-ETO is observed in long-term survivors, it seems obvious that it is residual leukemia that is responsible for relapse. The advent of modern real-time PCR techniques has enabled to quantify accurately residual leukemia and thus has provided deeper insight in the response to therapy and the dynamics of residual leukemic blasts. [12] [13] [14] [15] [16] AML with AML1-ETO rearrangements are generally regarded as the favorable entity. However, despite high complete hematological remission (CR) rates after standard induction therapy, more than 30% [17] [18] [19] of the patients relapsed. Several previous reports have analyzed risk factors, mainly based on patient characteristics and cytogenetic abnormalities. [17] [18] [19] The aim of this study was to analyze how the quality of molecular response to chemotherapy affected the outcome of patients. Therefore, AML1-ETO transcript levels were quantitatively analyzed in bone marrow samples at diagnosis, after induction and consolidation therapies In addition, it was examined whether type of induction therapy, patient or diseaserelated parameters influenced the quality of molecular response.
Patients and methods

Patients
The current study included a series of 45 patients with AML1-ETO-positive AML that were entered in the protocols AMLCG 92 and 99 of the German AML Cooperative Group (AMLCG) [20] [21] [22] between 1996 and 2005. The studies adhered to the declaration of Helsinki and were approved by the ethics committees of the participating institutions before initiation. All patients provided their written informed consent after having been informed about the investigational aims of the studies. All cases were diagnosed as AML according to the FAB or WHO classification [23] [24] [25] and all patients underwent complete cytogenetic and molecular genetic analyses at the Laboratory for Leukemia Diagnostics of the Department of Internal Medicine III.
In both studies, double induction therapy was applied for initial therapy that comprised either one cycle of 6-thioguanine, cytarabine, and daunorubicin (TAD9) followed by one cycle of high-dose cytosine arabinoside plus mitoxantrone (HAM) or two cycles of HAM. Consolidation therapy consisted of TAD9 for all followed by post-consolidation treatment as published previously. [20] [21] [22] Twenty-four patients received HAM/HAM induction therapy and 21 patients received TAD9/HAM induction therapy. Bone marrow samples of patients were quantitatively assessed for molecular response after induction and after consolidation therapy.
Cytomorphology
Cytomorphologic analysis was based on May-Grü nwaldGiemsa stains, myeloperoxidase reaction and non-specific esterase using a-naphthyl-acetate. 26 All stainings were performed centrally according to standard protocols.
Cytogenetics
Cytogenetic analysis was performed centrally according to standard protocols. 27 Cytogenetic data were classified according to the ISCN nomenclature. 28 
Molecular genetics
Quantification of AML1-ETO 12 and screening for KIT mutations 29 that were performed have been described in detail elsewhere. 16 Screening for KIT D816 mutations was available in 39 patients. A KIT D816 mutation was detected in 3/39 patients (8%).
Response criteria
Complete hematological remission was defined as o5% bone marrow blasts in cytomorphology plus normal hematopoesis of all cell lines and a restitution of a normal peripheral blood with at least 1500/ml neutrophils and at least 100 000/ml platelets. Relapse was defined as reinfiltration of the bone marrow of 45% or proven extramedullary leukemic infiltration.
Statistical analysis
Survival curves were calculated for overall survival (OS) from start of therapy using Kaplan-Meier estimates. For OS, events were defined as death from any cause. For event free survival (EFS), events were defined as persistent leukemia after induction therapy, death from any cause and relapse after achievement of hematological CR. Survival curves were compared using double-sided log rank test. Results were significant at a level of Po0.05 on both sides. Pearson's w-test was performed to assess differences between two cohorts. SPSS 12.0 for Windows software package (SPSS, Chicago, IL, USA) was used for statistical analysis.
Results
Patient characteristics
Patients had either the M1 (n ¼ 6) or M2 (n ¼ 39) subtype according to the FAB classification. t(8;21) and an AML1-ETO fusion transcript was diagnosed in all 45 AML cases. Further patient characteristics are shown in Table 1 and 2.
Remission rate, EFS and OS of the total cohort
A hematological CR after induction therapy was achieved in 43/45 (95.5%) patients (23/29 patients with follow-up samples after induction therapy and 35/37 patients with samples after consolidation therapy). Relapse after initial hematological CR occurred in 16/45 cases (37%). The median OS and EFS were 53 and 34 months, respectively.
Molecular genetics
The median AML1-ETO ratio expressed as 100xAML1-ETO/ABL was 47 (range 8-2067). In the total cohort, the median reduction of initial AML1-ETO transcript levels after induction and consolidation therapies was both 4 log (range 0-5 log). The median AML1-ETO expression level after induction therapy was 0.003 (range 0-37) and after consolidation therapy 0.003 (range 0-13). A Cox regression analysis of the reduction of initial AML1-ETO levels as continuous variable revealed that a better molecular response to induction and consolidation therapies was associated with improved cumulative incidence of relapse (CIR: P ¼ 0.021 and P ¼ 0.001, respectively), EFS (P ¼ 0.001 and P ¼ 0.001, respectively) and OS (P ¼ 0.013 and P ¼ 0.014, respectively). In addition, using log rank test, we analyzed the outcome of patients with molecular follow-up samples above or below the median AML1-ETO expression level after induction and consolidation therapies. After induction therapy, an AML1-ETO expression level below the median was associated with a lower incidence of relapse (P ¼ 0.080; Figure 1 ), a longer EFS (P ¼ 0.004; Figure 2 ) and OS (P ¼ 0.001; Figure 3 ) as compared to cases with AML1-ETO levels above the median. After consolidation therapy, an AML1-ETO expression level below the median was associated with a lower incidence of relapse (P ¼ 0.009; Figure 4 ), a longer EFS (P ¼ 0.006; Figure 5 ) and OS (P ¼ 0.079; Figure 6 ) as compared to cases with AML1-ETO levels above the median (Tables 3 and 4) . KIT D816 mutation 3
Abbreviation: AML, acute myeloid leukemia.
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Patient, disease and therapy-related factors
Disease or treatment-related factors influencing the quality of molecular response to therapy were analyzed. First, patient and disease-related factors as well as the type of induction therapy were analyzed with respect to the AML1-ETO expression level above or below the median after induction and consolidation therapies. These factors included age, sex, white blood cell (WBC) count, platelet count, bone marrow blast percentage, ethiology (de novo vs t-AML), additional cytogenetic aberrations, for example, loss of sex chromosome, AML1-ETO expression levels at diagnosis and the type of double induction therapy (HAM/HAM vs TAD9/HAM). The only parameter associated with improved molecular response to induction therapy was the type of therapy. Molecular response to therapy was improved when two consecutive cycles of HAM were administered as compared to TAD9 followed by HAM (P ¼ 0.042). However, after application of consolidation therapy (TAD9), no differences between these two types of induction therapies were detectable (P ¼ 0.231) ( Table 5 ). In addition, there was no evidence that the type of induction therapy per se had an impact on the outcome of the total cohort (n ¼ 45; OS: P ¼ 0.483, EFS: P ¼ 0.446).
Discussion
The present study focuses on the prognostic impact of the quality of molecular response after induction and consolidation therapies in AML1-ETO-positive AML. In addition, patient, disease, and therapy-related factors influencing the quality of molecular response to therapy were examined. It was demonstrated that the quality of molecular response after induction and consolidation therapies not only influenced The quality of molecular response to chemotherapy in AML1-ETO-positive AML M Weisser et al the incidence of relapse but also EFS and OS. It was shown that a greater reduction of initial AML1-ETO expression level was associated with improved outcome. In addition, it was possible to define a cutoff level of 0.003 -the median AML1-ETO expression level -after induction and consolidation therapies. This cutoff level provided deeper insight into the efficacy of the applied therapy than classical light microscopy alone. It also enabled risk assessment after each stage of therapy. To our knowledge, the present study demonstrates the largest homogenous study cohort on minimal residual disease (MRD) in AML1-ETO-positive AML and the first study on MRD in which therapeutic, patient and disease-related aspects are evaluated. With respect to improved outcome of lower MRD levels, we can confirm previous studies of other groups. [13] [14] [15] [16] 30 Stentoft and Krauter defined a cutoff level of 1% in initial AML1-ETO transcript levels. In our study, the median AML1-ETO level at diagnosis and after induction/consolidation therapy was 47 and 0.003, respectively. Thus, this is a reduction of 4 log or to 0.01%. In the present study, a reduction to 1% (2 log) did not provide a significant improvement of outcome as the vast majority of patients achieved a 42 log reduction of initial AML1-ETO expression levels after induction (83%) and after consolidation (86%) therapies. Differences in PCR protocols as well as differences in therapy may have caused these discrepancies.
In the second step, we examined factors that were associated with molecular response to induction therapy. As two different types of double induction therapy were applied, we analyzed the effect of therapy itself on the quality of molecular response. The sequential application of HAM was associated with superior molecular response as compared to TAD9 followed by HAM (P ¼ 0.042). Interestingly, after consolidation therapy with another cycle of TAD9, no differences between the two types of induction therapy were observed. This suggests that the improved molecular response to HAM/HAM induction therapy may be a short-term effect. Although Byrd et al. 17 demonstrated a beneficial outcome for AML1-ETO-positive patients when repetitive cycles of high-dose cytosine arabinoside were applied, no differences between HAM/HAM and TAD9/HAM double induction therapy were detectable in the report of the AML99 trial. 22 However, the latter analysis was restricted to cytogenetically defined prognostic groups rather than the t(8;21)-positive cohort as such. Thus, further investigation is warranted.
In addition, the established risk factors such as age, WBC count, platelet count and so on 18, 19 were examined. None of these factors had an impact on the quality of molecular response after induction or consolidation therapy. In the AMLCG trial, patients above 60 years received HAM with reduced dose of cytosine arabinoside (1 g/m 2 instead of 3 g/m 2 ). One would have assumed that the lower dose of cytosine arabinoside may have influenced molecular response. However, patients above the age of 60 years were underrepresented in the present analysis (n ¼ 6) and thus an age effect was not observed in the present study. Therapy-related AML (t-AML) showed good molecular response but again owing to low case numbers (n ¼ 4), these 
Abbreviations: CIR, cumulative incidence of relapse; EFS, event free survival; OS, overall survival.
Table 4
Quality of molecular response after consolidation therapy
Log reduction of initial AML1-ETO expression level (Cox regression analysis)
AML1-ETO/ABL Â 100 expression level below the median
The quality of molecular response to chemotherapy in AML1-ETO-positive AML M Weisser et al results have to be discussed cautiously. At least there was no evidence that t-AML responded worse to therapy than de novo AML. Recently it has been shown that KITD816 mutations were associated with a poor prognosis in AML1-ETO-positive AML. 29, 31, 32 In the patient cohort included in the present study, a KITD816 mutation was detected in only three patients. One patient had a good molecular response to therapy (o median AML1-ETO expression level), the other two patients had a worse molecular response to therapy (4median AML1-ETO expression level) and all three patients relapsed. Thus, despite low case numbers, the present analysis underlines the low curative potential for t(8;21)-positive AML patients with KITD816 mutations.
High initial AML1-ETO expression levels have been detected as risk factor by our group and others. 12, 15 In the present study, a higher than median or 475th percentile initial AML1-ETO transcript level had no influenced on the quality of molecular response. This does not contradict our previous results 12 as the previous study focused on the effect of initial transcript levels on the survival of patients, whereas the present study focuses on factors influencing the molecular response to therapy. Thus, the influence of initial transcript levels on the outcome of AML may be independent of the short-term effect on molecular response to induction or consolidation therapy.
In the previous study, 12 the kinetics of transcript reduction had an impact on survival only at the checkpoint postconsolidation therapy. However, owing to lower case numbers (AML1-ETO: n ¼ 18), three different AML subtypes (AML1-ETO, CBFB-MYH11, PML-RARA) were pooled for the MRD analysis. In the present study, we found a survival benefit for patients with lower transcript levels and better reduction of initial AML1-ETO transcript levels after induction and consolidation therapies. Larger case numbers -n ¼ 29 after induction therapy and n ¼ 37 after consolidation therapy-most likely have caused these discrepancies. In addition, after induction therapy, we also found rather high relapse rates in the group with improved molecular response (Figure 1 ). This suggests that the assessment of MRD after consolidation may be of higher predictive value than the assessment after induction therapy.
In conclusion, it was demonstrated that the level of reduction of initial AML1-ETO transcript level assessed by real-time quantitative PCR (RQ-PCR) after induction therapy is essential for the outcome of the disease. Most importantly, it was shown that quantitative assessment of molecular response provides deeper insight into the quality of remission and the long-term prognosis than the mere achievement of a cytomorphological CR. In addition, shortly after induction therapy, the quality of molecular response to chemotherapy was dependent on the type of therapy. Double induction with HAM/HAM provided improved molecular response. However this finding was a short-term effect and diminished after consolidation therapy.
Our study clearly demonstrates that for diagnostics and therapy of AML1-ETO-positive AML, quantitative assessment of AML1-ETO fusion transcripts at diagnosis and throughout the course of anti-leukemic therapy are essential. Standardized PCR protocols are necessary to compare molecular genetic results between different laboratories.
1 Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Abbreviations: HAM, high-dose cytosine arabinoside plus mitoxantrone; Hb, hemoglobin; TAD9, 6-thioguanine, cytarabine and daunorubicin; WBC, white blood cells.
